| Abstrakt: |
The article discusses the Joint EANM-SNMMI guideline on the use of [18F]FDG-PET/CT in breast cancer. It emphasizes the importance of this imaging technique in various situations, including initial staging, treatment response assessment, and detecting recurrence. The guideline considers the perspectives of different medical professionals to provide a comprehensive understanding of clinical implications and decision-making processes. The article also mentions advancements in breast cancer management and improved mortality rates due to better treatments and mammography screening. It further explores different subtypes of breast cancer based on hormone receptors and HER2 status, and how [18F]FDG-PET/CT staging can impact patient management and survival. The article concludes by highlighting the growing evidence for using [18F]FDG-PET/CT to assess early metabolic response during neoadjuvant therapy, and the potential of PET-based treatment strategies in clinical trials. It also discusses the usefulness of [18F]FDG-PET/CT in detecting recurrence and monitoring treatment response in metastatic breast cancer, particularly for bone metastases. The article mentions the use of other tracers, such as [18F]FES and HER2-targeting tracers, for predicting therapy response and providing a more comprehensive assessment of active lesions. Finally, it mentions emerging technologies like PET/MRI and dedicated breast PET that are being explored for breast cancer imaging. [Extracted from the article] |
Full text from SpringerLink